Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × pembrolizumab × 30 days × Clear all

Phase

Phase 2 86 Phase 3 79 Phase 1 58 Phase 1/2 51 Phase 2/3 6 Phase NA 5 Phase EARLY_PHASE1 3 Phase 4 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Non-Small Cell Lung Cancer Metastatic 1

Interventions

Prednisone 3 Carboplatin 3 enzalutamide 2 Injections 2 HMPL-013 2 Dexamethasone 2 Cisplatin 2 Cannabidiol 2 zanubrutinib 1 trastuzumab deruxtecan 1 trastuzumab biosimilar HLX02 1 toripalimab 1 testosterone 17 beta-cypionate 1 talquetamab 1 suvorexant 1 sofosbuvir-velpatasvir drug combination 1 ruxolitinib 1 rozanolixizumab 1 ribociclib 1 relatlimab 1 ravulizumab 1 pirtobrutinib 1 pembrolizumab 1 obinutuzumab 1 nirogacestat 1 niraparib 1 nilotinib 1 lenvatinib 1 ibrutinib 1 human papillomavirus vaccine, L1 type 16, 18 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05689671 2026-03-10

ANTELOPE

Charite University, Berlin, Germany

Phase 4 Active not recruiting

Non-Small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡